Gilead challenges ViiV in resistant HIV, filing twice-yearly therapyGilead Sciences has filed for FDA approval of a long-acting therapy for resistant HIV infections that only needs Share XGilead challenges ViiV in resistant HIV, filing twice-yearly therapyhttps://pharmaphorum.com/news/gilead-challenges-viiv-in-resistant-hiv-filing-twice-yearly-therapy/
Pair of R&D updates bolster GSK ahead of investor meetingGlaxoSmithKline (GSK) has reported encouraging data for its COVID-19 antibody sotrovimab, and an alliance with Halozyme to develop Share XPair of R&D updates bolster GSK ahead of investor meetinghttps://pharmaphorum.com/news/pair-of-rd-updates-bolster-gsk-ahead-of-investor-meeting/
ViiV’s Rukobia cleared in EU as rescue HIV therapyThe European Commission has given a green light to the use of ViiV Healthcare’s Rukobia as a treatment Share XViiV’s Rukobia cleared in EU as rescue HIV therapyhttps://pharmaphorum.com/news/viivs-rukobia-cleared-in-eu-as-rescue-hiv-therapy/
ViiV launches digital triage service for HIV patients with London hospitalViiV Healthcare and London’s Westminster Hospital NHS Foundation Trust have launched a digital triage service for HIV patients Share XViiV launches digital triage service for HIV patients with London hospitalhttps://pharmaphorum.com/news/viiv-launches-digital-triage-service-for-hiv-patients-with-london-hospital/
ViiV gets FDA nod for Rukobia drug for older HIV patientsThe FDA has approved Rukobia, a first-in-class drug from ViiV Healthcare intended for older people with HIV, who Share XViiV gets FDA nod for Rukobia drug for older HIV patientshttps://pharmaphorum.com/news/viiv-gets-fda-nod-for-rukobia-drug-for-older-hiv-patients/
ViiV’s two-drug HIV therapy Dovato gets Japanese approvalOne of ViiV Healthcare’s two-drug HIV therapies – Dovato – has been approved in Japan, providing a new Share XViiV’s two-drug HIV therapy Dovato gets Japanese approvalhttps://pharmaphorum.com/news/viivs-two-drug-hiv-therapy-dovato-gets-japanese-approval/
ViiV files first-in-class HIV drug in EuropeViiV Healthcare has filed its new HIV drug fostemsavir for approval in Europe, a few weeks after the Share XViiV files first-in-class HIV drug in Europehttps://pharmaphorum.com/news/viiv-files-first-in-class-hiv-drug-in-europe/
FDA knocks back ViiV, J&J’s long-acting HIV regimenPeople with HIV hoping to be freed from daily doses of tablets will have to wait a little Share XFDA knocks back ViiV, J&J’s long-acting HIV regimenhttps://pharmaphorum.com/news/fda-knocks-back-viiv-jjs-long-acting-hiv-regimen/
ViiV presses go on FDA filing for first-in-class HIV drug fostemsavirViiV Healthcare has fulfilled its pledge of submitting its new HIV drug fostemsavir for approval before year end, Share XViiV presses go on FDA filing for first-in-class HIV drug fostemsavirhttps://pharmaphorum.com/news/viiv-presses-go-on-fda-filing-for-first-in-class-hiv-drug-fostemsavir/
